Introduction
Persistent infection with high-risk genotypes of human papillomavirus (HPV) is the pathogenic cause of cervical cancer, and it is also associated with some anogenital cancers as well as head and neck cancers. 1, 2 At the present, prophylactic HPV vaccines are commercially available and can prevent the infection of most prevalent high-risk HPVs; however, they do not exert therapeutic effects on established infections and associated lesions. 3 Thus, a therapeutic vaccine is urgently needed. The HPV early protein E7 is considered one of the most potential antigen candidates for the development of a therapeutic vaccine because of its abundant and sustained expression in infected cells and tumor as well as its high conservation. E7-based vaccine candidates have been tested in HPV-associated animal models. A fusion protein combining E7, hepatitis B core antigen, and heat shock protein 65 (VR111) increased anti-HPV16 cellular immunity compared with E7 alone. 4 E7 chemically coupled to a bacterial lipid moiety stimulated the immune responses toward the T-helper (Th)1 type and induced E7-specific cytotoxic lymphocyte (CTL) responses. 5 The combination of the 2 fusion proteins PE(ÄIII)/E6 and PE(ÄIII)/E7 generated more potent antitumor effects than a single fusion protein. 6 Nevertheless, there have been only a few protein-based vaccines that proceeded to the phase of human clinical trials, mainly attributed to weak immune responses. Recently, nanoparticles are emerging as a promising vaccine form. Based on the delivery platform, immune responses can be modulated by modifying the stability, tissue and cell targeting, and the dendritic cell (DC) activation of antigen and adjuvant, and they can improve the microenvironment to facilitate the development of antitumor immunity. Largely, E7 peptides, instead of whole E7 proteins, have been carried by a variety of nanoparticles such as recombinant virus-like particles [7] [8] [9] [10] [11] or artificial particles, 12 which are limited by the compatibility of the particles. A good prospect would be a long peptide or even the full-length E7 protein, which holds more epitopes, and other novel nanoparticle platforms thus need to be explored. Outer membrane vesicles (OMVs) are naturally occurring proteoliposomes with a diameter of 20-250 nm that are released from Gram-negative bacteria by the budding of the outer membrane. [13] [14] [15] [16] The vesicles contain the bacterial outer membrane and periplasm components, including lipopolysaccharides, nucleotide acids, lipids, outer membrane proteins, periplasmic proteins, inner membrane proteins and cytoplasm proteins. [13] [14] [15] [16] [17] OMVs were found to be highly immunogenic and elicit efficient immune responses, independent of additional adjuvants, against the bacterium from which they were isolated. 16 However, their potential as a novel antigen delivery carrier has not been well studied. It has been shown that heterologous proteins can be genetically tethered to OMVs with a designated distribution. The bacterial hemolysin ClyA, which was fused to green fluorescent protein (GFP) and served as a leading polypeptide, was shown to be able to guide GFP to express on the surface of OMVs. 18, 19 While a twin arginine transporter anchor sequence was used, GFP was entrapped into the periplasmic space of the bacteria and thus located in the lumen of OMVs eventually. 20 OMVs have been shown to contribute to the Th1-biased immune response. 21 Whether OMVs are associated with an enhanced antigen-specific cellular immune response remains to be known.
In this study, the non pathogenic Escherichia coli DH5α strain was employed to prepare engineered OMVs displaying the HPV16 E7 protein. Utilizing the intrinsic immunological and structural features of OMVs, we sought to investigate whether the engineered OMVs could induce E7-specific cellular immunity and have significant therapeutic effects on established tumors in a mouse model of HPV infection, thus demonstrating the potential of using E. coli OMVs as a feasible antigen delivery platform for therapeutic tumor vaccines.
Materials and methods ethics statement
The animal experimental and welfare procedures were approved by the Ethics Committee of Animal Care and Welfare, Institute of Medical Biology, CAMS (Permit Number: SYXK (dian) 2010-0007), in accordance with the animal ethics guidelines of the Chinese National Health and Medical Research Council and the Office of Laboratory Animal Management of Yunnan Province, China. All efforts were made to minimize animal suffering.
Plasmid construction
The plasmid pThioHis A was purchased from Invitrogen, Inc. DNA fragments encoding for the HPV16E7 protein were synthesized commercially by Sangong, Inc. (Shanghai, China). The E7 gene was introduced into pThioHis A between BamH I and Sal I sites using gene recombinant techniques, allowing E7 to fuse at the C-terminus of thioredoxin (trx). The recombinant plasmid was transformed into competent E. coli DH5α cells.
expression of e7 and the preparation of OMVs and the trx-e7 fusion protein
The recombinant DH5α cells were grown in Luria-Bertani medium until the OD 600 value reached 0.4-0.6, and then the expression of trx-E7 was induced by adding isopropyl β-d-1-thiogalactopyranoside (IPTG) to 0.001 mol/L. OMVs were purified in accordance with a previously established procedure. 22 Briefly, 16 h after induction, the cell-free culture supernatants were collected by centrifugation at 14,000× g and 4°C for 20 min and then filtered through a 0.45-μm filter to clarify. The bacterial cells were preserved at -80°C for protein purification. The filtered supernatants were concentrated by ultrafiltration with a 500,000-nominal molecular weight cutoff (500,000 NMWC) column (QuixStand Benchtop 
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Engineered OMV is potent to elicit HPV16E7-specific cellular immunity System, GE Healthcare, Piscataway, NJ, USA). The vesicles were further collected by ultracentrifugation at 200,000× g and 4°C for 4 h (Beckman Coulter; TiSW28 rotor) and resuspended in PBS (0.02 M, 0.15 M NaCl, pH 7.2).
The gene encoding the fusion protein of trx and HPV16 E7 (trx-E7) was cloned into pThioHIsA between BamH I and Sal I. Its expression was induced with IPTG in DH5α cells, and the recombinant protein was purified by Ni 2+ -chelating chromatography. The amount of purified fusion protein and OMVs was identified using the total protein concentration, which was measured by the bicinchoninic acid method.
Immunoblotting analysis
OMV samples were loaded and separated on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels. The proteins were electrophoretically transferred to a polyvinylidene fluoride membrane (45 min, 20 V). The membranes were blocked with 5% skim milk in 0.02 M Tris HCl (pH 7.8) containing 0.036 M SDS and then incubated with a 1:200 dilution of the primary antibodies (goat anti-HPV16 E7 antibody; Santa Cruz Biotechnology Inc.), followed by treatment with horse reddish peroxidase-conjugated donkey anti-goat IgG antibodies (1:4,000; Santa Cruz Biotechnology Inc.). The blots were developed by the addition of an enhanced chemiluminescence substrate (Thermo Fisher Scientific).
Bone marrow-derived dendritic cells (BMDcs) isolation and culture BMDCs were isolated from murine according to a procedure described by Inaba et al 23 with minor modifications. In brief, the bone marrow was flushed from the tibias and femurs of 4-to 5-week-old male C57BL/6 mice and depleted of red blood cells (RBCs) using RBC Lysis Buffer (Sigma-Aldrich). The cells were plated in 6-well culture plates (1×10 6 cells per mL; 3 mL per well) in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL streptomycin and 20 ng/mL recombinant mouse granulocyte-macrophage colony-stimulating factor at 37°C in 5% CO 2 . On days 2 and 4 of culturing, the floating cells were gently removed, and fresh medium was added. On day 6 of culture, nonadherent cells and loosely adherent proliferating DC aggregates were harvested for analysis or stimulation.
GFP delivery into RAW 264.7 cells by OMVs
To determine if the mimetic antigen could be delivered successfully into RAW 264.7 cells and if OMVs could be taken up by RAW 264.7 cells, OMVs displaying GFP (GFP-OMVs) and Dio-labeled OMVs were used. RAW 264.7 cells are macrophages derived from Abelson murine ascites, and they were purchased from the American Type Culture Collection. Wild-type OMVs (wt OMVs, 1 mg OMV protein/mL) were labeled with 1% (v/v) fluorescence dye Dio (Molecular Probes) at 37°C for 20 min. They were then centrifuged at 5,000× g and washed with PBS for 3 times in a 100-kDa ultrafiltration centrifuge tube. A total of 1 mL of 1×10 6 /mL cells per well was cultured in a 6-well plate. Engineered OMVs 0, 50 or 100 μg presenting GFP (GFP-OMVs) were added into the plate with 6 wells for each concentration. After 4 h, the cells were washed with PBS for 3 times (5 min each time). For each OMV concentration, 3 wells of cells were examined using a fluorescent microscope, and the other 3 wells of cells were digested with 0.25% trypsin and analyzed by flow cytometry.
Flow cytometry analysis of OMVs uptake by DCs and their maturation

1×10
6 /mL DCs were incubated with 50 μg/mL recombinant OMVs presenting E7 (trx-E7 OMVs), wt OMVs or recombinant trx-E7 fusion protein for 24 h. The cells were resuspended in flow cytometry staining buffer and stained with the anti-CD11c-PE, anti-CD80-fluorescein isothiocyanate (FITC), anti-CD86-FITC, anti-CD83-FITC or anti-CD40-FITC antibodies (eBioscience) for 30 min at 4°C in the dark. The expression levels of the maturation markers of DCs were analyzed using a flow cytometer.
To monitor the kinetics of the OMVs taken up by DCs and assess the importance of the OMV vesicular structure, different concentrations of FITC (Isomer I; Sigma-Aldrich)-labeled OMVs or ultrasonication-treated OMVs (vesicle structure was destroyed) were added to 1×10 5 /mL DCs and incubated at 37°C. Cell samples were taken at 1 h and stained with a PE-labeled anti-CD11c antibody. The fluorescent intensities of the cells were measured using a FACScan flow cytometer (BD Accuri™ C6; BD Biosciences, Germany). 
OMVs immunization and tumor model
Mice were injected subcutaneously (sc) on the right flank with 1×10
5 TC-1 tumor cells per mouse. When the tumors reached 2-3 mm in diameter, the mice were assigned to 5 groups as follows to receive different treatments: 10 μg of trx-E7 OMVs, 10 μg of wt OMVs, 10 μg of wt OMVs mixed with 0.1 μg of trx-E7 protein, 0.1 μg of trx-E7 protein combined with Freund's adjuvant and PBS as a control. Mice were injected sc 3 times at 7-day intervals.
The tumor volume was measured every other day starting on day 13. The mice were sacrificed when the largest tumor reached an ethical point. Spleens were collected for the isolation and preparation of splenocytes according to the instructions for the use of the lymphocyte separation medium used (Dakewe Biotech Co., Ltd., Shenzhen, China). In brief, the splenocytes were dispersed using 70-μm cell strainers and suspended in 5-mL lymphocyte separation medium, covered with 500 μL RPMI 1640 medium. They were then centrifuged at 800× g for 30 min. Then, the white cell layer was removed into a new tube. The cells were washed with fresh RPMI 1640 medium and then centrifuged at 500× g for 7 min. The final splenocytes were resuspended in complete RPMI 1640 culture medium for use. For flow cytometry analysis, the cells were stimulated with an HPV16 E7 peptide (amino acids 44-62) overnight or phorbol myristate acetate (PMA) and ionomycin for 5 h. Then, the cells were stained with the anti-CD8-PE and anti-interferon-gamma (IFNγ)-antigen-presenting cell (APC) or anti-CD4-FITC and anti-IFNγ-APC or anti-IL4-PE antibodies for analyzing T-cell immune responses with flow cytometry.
Measurement of antigen-specific IgG by enzyme-linked immunosorbent assay (elIsa)
After the mice were sacrificed, the sera were collected. Ninety-six well microplates were coated with 5 μg/mL E7 protein per well. Subsequently, the serum samples were added at various dilutions, and they were incubated with biotin-conjugated anti-mouse IgG at 1:10,000. Alkaline phosphatase-conjugated avidin was added, and the reaction was developed using the alkaline phosphatase substrate. The OD 405 values were detected with an ELISA reader.
Antigen-specific cellular response measured by enzyme-linked immunospot (elIsPOT) Splenocytes were obtained as described in the OMVs immunization and tumor model section. Splenocytes at 1×10 5 were separated and cultured in the presence of HPV16 E7 peptide (amino acids 44-62) at 10 μg/mL for 16-20 h. The cells stimulated with PMA and ionomycin were used as positive controls, and the cells incubated with medium only were used as negative controls. The number of antigen-specific IFNγ-producing cells was measured using an ELISPOT kit according to the manufacturer's instructions (Dakewe Biotech Co., Ltd.). The spots were counted using an automated analyzer (AID, Germany).
Statistical analysis
The significance of differences between experimental groups was analyzed using one-way analysis of variance followed by Tukey's multiple-comparisons test, or unpaired Student's t-test (GraphPad Prism 5.0; GraphPad Software, Inc.). Values are reported as the mean ± SD.
Results
The HPV16 E7 protein was successfully presented in engineered E. coli-derived OMVs sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed that the HPV16 E7 protein was efficiently expressed in E. coli DH5α cells mainly as the soluble fusion protein trx-E7 ( Figure 1A ). Semiquantitative analysis of the SDS/PAGE gel-band densitometry indicated that trx-E7 was ~1% of the total protein content in OMVs. Furthermore, the presence of the trx-E7 fusion protein in both E. coli whole cells and engineered OMVs samples was confirmed by immunoblotting with the detection of E7-specific antibodies ( Figure 1B) . The result indicated that trx-E7 was introduced into OMVs through the guidance of trx, which has the capability of moving into the cell periplasm space. Additionally, EDTA treatment can destroy the intact vesicular structure and expose the proteins in the inner lumen of OMVs; however, this did not change the content of OMVs ( Figure 1B) . Using proteinase K (PK) and/or EDTA treatment, followed by immunoblotting with E7-specific antibodies, E7 was shown to be partly exposed on the surface and partly encapsulated in the lumen of the engineered OMVs ( Figure 1B) .
Observation under an electron microscope showed that the morphologies of the wt OMVs and trx-E7 OMVs were similar. They had a spherical vesicle structure, and the size ranged from 20 to 200 nm, with an average diameter 
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Engineered OMV is potent to elicit HPV16E7-specific cellular immunity of 100 nm ( Figure 1C) . Dynamic light scattering analysis confirmed the identical size distribution of wt OMVs and trx-E7 OMVs. For wt OMVs, the maximum peak values were ~131 nm, and the polydispersity index (PdI) was ~0.301. For trx-E7 OMVs, the maximum peak values were ~125 nm, and the PdI was ~0.305 ( Figure 1D ). This demonstrated that the morphology of the engineered OMVs was not altered by the incorporation of a heterologous protein.
Vesicle structure was important for OMVs uptake by DCs, and OMVs significantly induced DC maturation (Figure 2A) . DCs are the most powerful and professional APCs, as they play critical roles in determining both the immune response direction and intensity. To assess the characteristics of the uptake of OMVs by DCs, FITClabeled OMVs and ultrasonication-treated OMVs, which lost vesicle structure, were incubated with BMDCs. As shown in Figure 2B , original OMVs have shown to be typical vesicles, while ultrasonication-treated OMVs displayed wizened and irregular morphology. The FITC-labeled proteins have a covalent bond that is not affected when we use ultrasonication to destroy the vesicle structure of OMV, and they were used as a control. The results showed that the numbers of the cells 
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Wang et al with fluorescence were up to 23.4% and 41.1% of the total cells treated with 2 and 10 μg/mL OMVs, respectively, at 60 min, while they were 5.07% and 18.5%, respectively, in cells treated with OMVs receiving ultrasonication treatment. This indicated that the vesicle structure of OMVs significantly enhanced the uptake efficacy of DCs ( Figure 2B) .
To assess the ability of OMVs to stimulate DC maturation, the expression levels of the surface molecules served as markers of DC maturation were measured in the cells incubated with trx-E7 OMVs, wt OMVs, trx-E7 protein and PBS. With or without trx-E7, OMVs induced the elevated expression of CD80, CD86, CD83 and CD40, which were dramatically higher than those induced by E7 protein alone and PBS ( Figure 2C) . Correspondingly, the production of tumor necrosis factor-alpha, a major tumor-killing cytokine, was shown to be stimulated significantly in OMVs-treated cells compared with that in trx-E7 protein and PBS-treated cells ( Figure 2D ). 
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Wang et al ( Figure 3A ) was significantly higher in trx-E7 OMV-vaccinated mice than in mice receiving trx-E7 protein mixed with OMVs, wt OMVs, or PBS (p,0.05). This indicated that trx-E7 OMVs were able to potently elicit an antigenspecific cellular immune response. Furthermore, E7-specific antibodies were detected by ELISA. The result showed that the specific antibodies were induced in trx-E7 OMVsimmunized mice, with a titer reaching 1×10 5 ( Figure 3B ), which is the reciprocal of the highest dilution of the sample in which the OD 405 value was twice of that of the corresponding control serum. The above results indicated that engineered OMVs presenting a specific antigen were highly immunogenic and could efficiently induce both cellular and humoral immune responses.
Therapeutic immunization with OMVs presenting e7 inhibited Tc-1 tumor growth
To investigate the therapeutic efficacy of the antitumor cellular immunity caused by the engineered OMVs, an HPV infection-associated tumor model and a treatment vaccination strategy were employed. TC-1 cells were inoculated into C57BL/6 mice first, and OMVs were immunized after the tumor was established ( Figure 4A ). The tumor growth trend ( Figure 4B ) and tumor weight at the endpoint of the experiment ( Figure 4C) showed that the engineered OMVs presenting E7 suppressed tumor growth significantly comparing with the data from mice receiving wt OMVs, OMVs mixed with trx-E7 protein or trx-E7 protein along with Freund's adjuvant. There were no apparent differences among the mice immunized with the trx-E7 protein mixed with OMVs or Freund's adjuvant, and the mice served as model controls. The results indicated that the presence of a specific antigen E7 in OMVs, not simply adjuvanted by OMVs, or with Freund's adjuvant were quite important for the efficient induction of antitumor immunity and suppression of tumor growth.
Correspondingly, when analyzed by flow cytometry, the level of CD8 + IFNγ + T cells in trx-E7 OMV-immunized mice was significantly elevated, while the level in mice receiving trx-E7 protein mixed with OMVs or Freund's adjuvant remained at a similar level to the control mice ( Figure 5A ). Furthermore, it is known that CD4 + T cells can be polarized into Th1 cells functionally to assist in the production and maintenance of the key antitumor effector cells, CTLs, while Th2 cells may contribute to immunosuppressive Figure 3 Immunization with engineered trx-E7 OMVs induced an E7-specific immune response. Notes: (A) An E7-specific cellular immune response was detected using an ELISPOT. Mice were immunized weekly 3 times. Their splenocytes were harvested 7 days after the last immunization using lymphocyte separation medium and incubated with HPV16 E7 (44-62) peptide for 16-20 h. Positive control wells were stimulated by PMA and Ionomycin. Negative control wells were stimulated by RPMI 1640 complete medium. Left: representative pictures; right: statistical data. *p,0.01 (n=3). (B) E7-specific IgG responses were evaluated by an ELISA at OD 405 with the antiserum dilutions 1:100, 1:1,000, 1:10,000 and 1:100,000. Abbreviations: ELISPOT, enzyme-linked immunospot assay; IgG, Immunoglobulin G; OD, optical density; OMVs, outer membrane vesicles; PBS, phosphate buffer solution; PMA, phorbol-12-myristate-13-acetate; RPMI, Roswell Park Memorial Institute; trx, thioredoxin; wt, wild type. 
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Engineered OMV is potent to elicit HPV16E7-specific cellular immunity microenvironments. 24 To verify the spleen-derived Th-cell bias, in vitro-stimulated splenic lymphocytes were analyzed using flow cytometry, and the results showed that compared with the PBS-treated and trx-E7 protein-treated groups, the levels of IFNγ-expressing CD4 + T cells in trx-E7 OMVimmunized mice were significantly higher than those of the mice receiving wt OMVs, trx-E7 protein mixed with wt OMVs, trx-E7 protein mixed with Freund's adjuvant or PBS ( Figure 5B ). The response of IL4-expressing CD4 + T cells showed no significant differences in all the groups ( Figure 5C ). Taken together, OMVs promoted T-cell responses to polarize the Th1/CTL subtypes.
Discussion
In this study, a novel nano-vesicle antigen delivery platform of E. coli-derived OMV was investigated to assess its potential in eliciting cellular immunity and developing a therapeutic cancer vaccine. Recently, OMVs have received increased attention as an emerging and feasible vaccine carrier 25 because of their distinct immunological and structural features, including the nanometer-scale vesicle structure, self-adjuvant effectiveness, ability to be genetically modified, tolerance of presenting exogenous large proteins and ability to carry immune stimulators. 25 However, the related studies are just in their infancy, especially research concerning their application potentials in stimulating specific cellular immunity. Using OMVs as a carrier, even large antigen proteins could be delivered, and more importantly, antigen and immune stimulators that enhance the intensity of immune responses and modulate the direction of the response could be delivered to the same APCs simultaneously and facilitate the production of a robust and proper type of antigen-specific immune response.
Trx-like proteins have a critical role in the redox biology of cells. The system is of particular significance in the periplasm of pathogenic bacteria, where disulfide bond 
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Wang et al formation is essential for both the motility and folding of a variety of toxins and secreted enzymes. 26, 27 Therefore, trx is widely used as a molecular chaperone for the efficient expression and proper folding of heterogenous proteins in the form of fusion proteins. In addition, trx has the ability to transport into the periplasm space. Thus, we deduced that trx ought to be used as a rational leader protein to mediate soluble antigen expression and translocation to the periplasm, allowing the further encapsulation into the lumen during OMV production. Our results confirmed that trx was an effective leading protein when preparing engineered OMVs, and SDS-PAGE and western blot analyses showed E7 was successfully enclosed in OMVs. We used a method described by Kim et al to determine the location of heterogeneous proteins on OMVs. 19 When roughly analyzed with PK and/or EDTA treatment, combined with immuno-blotting analyses, we found that E7 was presented both on the surface and in the lumen of OMVs.
Some of the OMV components are pathogen-associated molecular patterns, which are recognized by the innate arm or the first defensive line of the immune system and sensed by pattern recognition receptors, such as Toll-like receptors, thus driving the inflammatory response in conjunction with complement system activation. [28] [29] [30] It has been reported that the immunological characteristics of OMVs endow them with distinct capabilities to stimulate both innate and adaptive immunity in vitro and in vivo. [31] [32] [33] [34] [35] In addition, OMVs have a bilayer biomembrane structure containing proteins, polysaccharides, and lipids, allowing multiple possible mechanisms to mediate the entry of OMVs into APCs, including receptormediated entrance, and it has been reported that OMVs can transport materials into cells through membrane fusion. GFP is a protein with structure-dependent fluorescent activity, and uptaken GFP is subjected to proteinase digestion in the endosome/lysosome. OMVs labeled with Dio, which is a small molecule dye, highly retained their fluorescence 
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Engineered OMV is potent to elicit HPV16E7-specific cellular immunity in a long-lasting pattern, as shown in Figure 2A . We isolated mouse BMDCs and compared the capacity of OMVs and non-vesicle OMV components (the vesicle structure was destroyed by ultrasonic treatment) to deliver antigens into DCs and stimulate DC maturation. Our results showed that OMVs were taken up by DCs more quickly than non-vesicle OMV, which strongly indicated the importance of the vesicle structure of engineered OMVs.
In this study, we used a vaccination treatment strategy to assess the efficacy of engineered OMVs on eliciting antitumor immunity. We found that the OMVs presenting E7, even without the use of a conventional adjuvant, significantly suppressed TC-1 growth, whereas recombinant E7 protein mixed with OMVs or Freund' adjuvant did not show tumor suppression when compared with the model control and wt OMVs control. We also assessed E7-specific IgG, and again, the results confirmed that the presentation of E7 by OMVs was critical to induce specific antibody responses. We further analyzed IFNγ expressing lymphocytes in the spleen by ELISPOT and CD8
+ cells and CD8 + IFNγ + cells in the spleen by flow cytometry, and we found that they were significantly enhanced in engineered trx-E7 OMV-immunized mice. In addition, we found the level of CD4 + IFNγ + cells were elevated, whereas that of CD4 + IL4 + cells in the spleen was not affected significantly, indicating trx-E7 OMV immunization induced Th1/CTL-biased responses. The enhanced Th1/CTLs responses in trx-E7 OMV-immunized mice were probably due to the increased uptake of E7, the elevated cross-presentation through vesicle delivery and the simultaneous delivery of immune stimulators and antigens in APCs. The results strongly indicated the importance of E7 to be carried by the vesicles rather than mixed with OMVs or a strong adjuvant, such Freund's adjuvant, indicating that presence in the OMVs endows the high immunogenicity of the tumor antigen.
In this study, the engineered trx-E7 OMVs contained only ~1% of E7 out of the total OMV proteins, which is similar to the level reported by other groups (ranging from 0.32% to 0.8%). 20, 36 However, E7-specific immune responses were induced successfully, which strongly indicates the potent immunological effects of OMVs to serve as a vaccine carrier. There were some concerns raised about using OMVs as a conventional vaccine platform. First, immune responses directed to the carrier itself may affect the repeated use of a vaccine based on the same antigen delivery platform. It was reported that preexisting anti-carrier antibodies may mediate antibody-dependent phagocytosis and promote antigen clearance, thus reducing antigen uptake by APCs and weakening the subsequent immune responses. However, anti-carrier antibodies may not produce significant adverse effects, and there are also reports showing that preexisting antibodies enhanced immune responses by promoting the antigen uptake of APCs. Second, undesired responses to OMV components may excessively consume the responses of the immune system and thus attenuate the specific responses to the target antigen. Although we did not investigate how long the antibodies against the carrier and anti-carrier immune memory will persist and whether a preexisting antibody or how strongly the antibody responses will affect the repeated use of the vaccine, we clearly demonstrated that an OMVbased vaccine efficiently induced both specific humoral and cellular immune responses in the current study. It is also worth mentioning that even if preexisting anti-carrier antibodies may have adverse influences on the repeated use of OMV-based vaccines with different antigens, considering the unique features of OMVs as a vaccine platform, it will still be of value to employ an OMV-based vaccine in a prime-boost strategy for vaccination as well as other situations where other vaccine forms do not work well.
Conclusion
In summary, OMVs could present the complete E7 protein.
Immunization with trx-E7 OMVs produced a strong E7-specific cellular immunity response in mice, even without the use of conventional adjuvants, and trx-E7 OMV immunization suppressed the growth of grafted tumors in mice. These results indicated that OMVs could be utilized as a new and feasible antigen delivery platform for vaccines to induce therapeutic cellular immunity.
